Retroperitoneal fibrosis caused by pergolide in a patient with Parkinson's disease


Bilici A., Karadag B. , Doventas A., Erdincler D., Cetinkaya S., Ogut G., et al.

NETHERLANDS JOURNAL OF MEDICINE, cilt.62, ss.389-392, 2004 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 62 Konu: 10
  • Basım Tarihi: 2004
  • Dergi Adı: NETHERLANDS JOURNAL OF MEDICINE
  • Sayfa Sayısı: ss.389-392

Özet

Retroperitoneal fibrosis (RPF) is an uncommon disorder that may cause ureteric obstruction with renal damage. Pergolide, a dopaminergic agonist used in the treatment of Parkinson's disease, has rarely been related to the development of RPF. We report on a 78-year-old woman with Parkinson's disease who presented with hydroureteronephrosis and developed RPF and serosal fibrosis during treatment with pergolide. Following discontinuation of pergolide therapy and placement of a double-J stent, her renal function improved. Inflammatory markers returned to normal limits within two months and the retroperitoneal fibrotic mass became smaller.